New England Journal of Medicine最新文献

{"title":"Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.","authors":"Christina Magnussen, Jesus Alegre-Diaz, Lubna A Al-Nasser, Philippe Amouyel, Larissa Aviles-Santa, Stephan J L Bakker, Christie M Ballantyne, Antonio Bernabé-Ortiz, Martin Bobak, Paolo Boffetta, Hermann Brenner, Mattias Brunström, Gunay Can, Rodrigo M Carrillo-Larco, William Checkley, Jean Dallongeville, Dirk De Bacquer, Giovanni de Gaetano, James A de Lemos, Eleonora di Carluccio, Annette Dobson, Chiara Donfrancesco, Marcus Dörr, Eleonora d'Orsi, Wojciech Drygas, Robin P F Dullaart, Gunnar Engström, Marco M Ferrario, Jean Ferrières, Gemma A Figtree, Bamba Gaye, Majid Ghayour-Mobarhan, Uri Goldbourt, Clicerio Gonzalez, Alina Gossling, Guido Grassi, Prakash C Gupta, Jiang He, Allison M Hodge, Atsushi Hozawa, Kristian Hveem, Licia Iacoviello, M Kamran Ikram, Manami Inoue, Vilma Irazola, Modou Jobe, Pekka Jousilahti, Pontiano Kaleebu, Maryam Kavousi, Frank Kee, Davood Khalili, Jens Klotsche, Wolfgang Koenig, Anna Kontsevaya, Sudhirsen Kowlessur, Pablo Kuri-Morales, Kari Kuulasmaa, Sun-Seog Kweon, Karl J Lackner, Ulf Landmesser, David M Leistner, Carlos E Leiva Sisnieguez, Darryl Leong, Lars Lind, Allan Linneberg, Thiess Lorenz, Magnus N Lyngbakken, Reza Malekzadeh, Sofia Malyutina, Ellisiv B Mathiesen, Patrick McElduff, Olle Melander, Andres Metspalu, J Jaime Miranda, Marie Moitry, Joseph Mugisha, Julia Munzinger, Mahdi Nalini, Vijay Nambi, Peter M Nilsson, Toshiharu Ninomiya, Torbjørn Omland, Sok King Ong, Karen Oppermann, Andrzej Pajak, Luigi Palmieri, Demosthenes Panagiotakos, Sue K Park, Mangesh S Pednekar, Arokiasamy Perianayagam, Annette Peters, Hossein Poustchi, Dorairaj Prabhakaran, Andrew M Prentice, Eva Prescott, Arshed Quyyumi, Ulf Risérus, Satoko Sakata, Martin Salazar, Veikko Salomaa, Susana Sans, E Lilian P Sattler, Ben Schöttker, Aletta E Schutte, Sadaf G Sepanlou, Sanjib K Sharma, Jonathan Shaw, Leon A Simons, Stefan Söderberg, Abdonas Tamosiunas, Roberto Tapia-Conyer, Barbara Thorand, Hugh Tunstall-Pedoe, Jaakko Tuomilehto, Raphael Twerenbold, Diego Vanuzzo, Giovanni Veronesi, S Goya Wannamethee, Masafumi Watanabe, Jessica Weimann, Philipp S Wild, Yao Yao, Yi Zeng, Andreas Ziegler, Francisco M Ojeda, Stefan Blankenberg","doi":"10.1056/NEJMoa2415879","DOIUrl":"https://doi.org/10.1056/NEJMoa2415879","url":null,"abstract":"<p><strong>Background: </strong>Five risk factors account for approximately 50% of the global burden of cardiovascular disease. How the presence or absence of classic risk factors affects lifetime estimates of cardiovascular disease and death from any cause remains unclear.</p><p><strong>Methods: </strong>We harmonized individual-level data from 2,078,948 participants across 133 cohorts, 39 countries, and 6 continents. Lifetime risk of cardiovascular disease and death from any cause was estimated up to 90 years of age according to the presence or absence of arterial hypertension, hyperlipidemia, underweight and overweight or obesity, diabetes, and smoking at 50 years of age. Differences in life span (in terms of additional life-years free of cardiovascular disease or death from any cause) according to the presence or absence of these risk factors were also estimated. Risk-factor trajectories were analyzed to predict lifetime differences according to risk-factor variation.</p><p><strong>Results: </strong>The lifetime risk of cardiovascular disease was 24% (95% confidence interval [CI], 21 to 30) among women and 38% (95% CI, 30 to 45) among men for whom all five risk factors were present. In the comparison between participants with none of the risk factors and those with all the risk factors, the estimated number of additional life-years free of cardiovascular disease was 13.3 (95% CI, 11.2 to 15.7) for women and 10.6 (95% CI, 9.2 to 12.9) for men; the estimated number of additional life-years free of death was 14.5 (95% CI, 9.1 to 15.3) for women and 11.8 (95% CI, 10.1 to 13.6) for men. As compared with no changes in the presence of all risk factors, modification of hypertension at an age of 55 to less than 60 years was associated with the most additional life-years free of cardiovascular disease, and modification of smoking at an age of 55 to less than 60 years was associated with the most additional life-years free of death.</p><p><strong>Conclusions: </strong>The absence of five classic risk factors at 50 years of age was associated with more than a decade greater life expectancy than the presence of all five risk factors, in both sexes. Persons who modified hypertension and smoking in midlife had the most additional life-years free of cardiovascular disease and death from any cause, respectively. (Funded by the German Center for Cardiovascular Research [DZHK]; ClinicalTrials.gov number, NCT05466825.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).","authors":"Steven E Nissen, Wei Ni, Xi Shen, Qiuqing Wang, Ann Marie Navar, Stephen J Nicholls, Kathy Wolski, Laura Michael, Axel Haupt, John H Krege","doi":"10.1056/NEJMoa2415818","DOIUrl":"https://doi.org/10.1056/NEJMoa2415818","url":null,"abstract":"<p><strong>Background: </strong>Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepatic synthesis of lipoprotein(a), are unknown.</p><p><strong>Methods: </strong>We randomly assigned participants in a 1:2:2:2:2 ratio to receive lepodisiran at a dose of 16 mg, 96 mg, or 400 mg at baseline and again at day 180, lepodisiran at a dose of 400 mg at baseline and placebo at day 180, or placebo at baseline and at day 180, all administered by subcutaneous injection. Data from the two groups that received lepodisiran at a dose of 400 mg at baseline were pooled for the primary analysis. The primary end point was the time-averaged percent change from baseline in the serum lipoprotein(a) concentration (lepodisiran difference from placebo [i.e., placebo-adjusted]) during the period from day 60 to day 180.</p><p><strong>Results: </strong>A total of 320 participants underwent randomization; the median baseline lipoprotein(a) concentration was 253.9 nmol per liter. The placebo-adjusted time-averaged percent change from baseline in the serum lipoprotein(a) concentration from day 60 to day 180 was -40.8 percentage points (95% confidence interval [CI], -55.8 to -20.6) in the 16-mg lepodisiran group, -75.2 percentage points (95% CI, -80.4 to -68.5) in the 96-mg group, and -93.9 percentage points (95% CI, -95.1 to -92.5) in the pooled 400-mg groups. The corresponding change from day 30 to day 360 was -41.2 percentage points (95% CI, -55.4 to -22.4), -77.2 percentage points (95% CI, -81.8 to -71.5), -88.5 percentage points (95% CI, -90.8 to -85.6), and -94.8 percentage points (95% CI, -95.9 to -93.4) in the 16-mg, 96-mg, 400-mg-placebo, and 400-mg-400-mg dose groups, respectively. Serious adverse events, none of which were deemed by investigators to be related to lepodisiran or placebo, occurred in 35 participants. Dose-dependent, generally mild injection-site reactions occurred in up to 12% (8 of 69) of the participants in the highest lepodisiran dose group.</p><p><strong>Conclusions: </strong>Lepodisiran reduced mean serum concentrations of lipoprotein(a) from 60 to 180 days after administration. (Funded by Eli Lilly; ALPACA ClinicalTrials.gov number, NCT05565742.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation.","authors":"Sergio Raposeiras-Roubin, Ignacio J Amat-Santos, Xavier Rossello, Rocío González Ferreiro, Inmaculada González Bermúdez, Diego Lopez Otero, Luis Nombela-Franco, Livia Gheorghe, Jose L Diez, Carlos Baladrón Zorita, José A Baz, Antonio J Muñoz García, Victoria Vilalta, Soledad Ojeda-Pineda, José M de la Torre Hernández, Juan G Cordoba Soriano, Ander Regueiro, Pascual Bordes Siscar, Jorge Salgado Fernández, Bruno Garcia Del Blanco, Roberto Martín-Reyes, Rafael Romaguera, César Moris, Sergio García Blas, Juan A Franco-Peláez, Ignacio Cruz-González, Dabit Arzamendi, Nieves Romero Rodríguez, Felipe Díez-Del Hoyo, Santiago Camacho Freire, Francisco Bosa Ojeda, Juan C Astorga Burgo, Eduardo Molina Navarro, Juan Caballero Borrego, Valeriano Ruiz Quevedo, Ángel Sánchez-Recalde, Vicente Peral Disdier, Eduardo Alegría-Barrero, Javier Torres-Llergo, Gisela Feltes, José A Fernández Díaz, Carlos Cuellas, Gustavo Jiménez Britez, Juan Sánchez-Rubio Lezcano, Cristina Barreiro-Pardal, Iván Núñez-Gil, Emad Abu-Assi, Andrés Iñiguez-Romo, Valentín Fuster, Borja Ibáñez","doi":"10.1056/NEJMoa2500366","DOIUrl":"https://doi.org/10.1056/NEJMoa2500366","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), have been excluded from randomized trials.</p><p><strong>Methods: </strong>We conducted this randomized, controlled trial in Spain to evaluate the efficacy of dapagliflozin (at a dose of 10 mg once daily) as compared with standard care alone in patients with aortic stenosis who were undergoing TAVI. All the patients had a history of heart failure plus at least one of the following: renal insufficiency, diabetes, or left ventricular systolic dysfunction. The primary outcome was a composite of death from any cause or worsening of heart failure, defined as hospitalization or an urgent visit, at 1 year of follow-up.</p><p><strong>Results: </strong>A total of 620 patients were randomly assigned to receive dapagliflozin and 637 to receive standard care alone after TAVI; after exclusions, a total of 1222 patients were included in the primary analysis. A primary-outcome event occurred in 91 patients (15.0%) in the dapagliflozin group and in 124 patients (20.1%) in the standard-care group (hazard ratio, 0.72; 95% confidence interval [CI], 0.55 to 0.95; P = 0.02). Death from any cause occurred in 47 patients (7.8%) in the dapagliflozin group and in 55 (8.9%) in the standard-care group (hazard ratio, 0.87; 95% CI, 0.59 to 1.28). Worsening of heart failure occurred in 9.4% and 14.4% of the patients, respectively (subhazard ratio, 0.63; 95% CI, 0.45 to 0.88). Genital infection and hypotension were significantly more common in the dapagliflozin group.</p><p><strong>Conclusions: </strong>Among older adults with aortic stenosis undergoing TAVI who were at high risk for heart-failure events, dapagliflozin resulted in a significantly lower incidence of death from any cause or worsening of heart failure than standard care alone. (Funded by Instituto de Salud Carlos III and others; ClinicalTrials.gov number, NCT04696185.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.","authors":"Darren K McGuire, Nikolaus Marx, Sharon L Mulvagh, John E Deanfield, Silvio E Inzucchi, Rodica Pop-Busui, Johannes F E Mann, Scott S Emerson, Neil R Poulter, Mads D M Engelmann, Maria Sejersten Ripa, G Kees Hovingh, Kirstine Brown-Frandsen, Stephen C Bain, Matthew A Cavender, Mette Gislum, Jens-Peter David, John B Buse","doi":"10.1056/NEJMoa2501006","DOIUrl":"https://doi.org/10.1056/NEJMoa2501006","url":null,"abstract":"<p><strong>Background: </strong>The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both is needed.</p><p><strong>Methods: </strong>In this double-blind, placebo-controlled, event-driven, superiority trial, we randomly assigned participants who were 50 years of age or older, had type 2 diabetes with a glycated hemoglobin level of 6.5 to 10.0%, and had known atherosclerotic cardiovascular disease, chronic kidney disease, or both to receive either once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care. The primary outcome was major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke), assessed in a time-to-first-event analysis. The confirmatory secondary outcomes included major kidney disease events (a five-point composite outcome).</p><p><strong>Results: </strong>Among the 9650 participants who had undergone randomization, the mean (±SD) follow-up was 47.5±10.9 months, and the median follow-up was 49.5 months. A primary-outcome event occurred in 579 of the 4825 participants (12.0%; incidence, 3.1 events per 100 person-years) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%; incidence, 3.7 events per 100 person-years) in the placebo group (hazard ratio, 0.86; 95% confidence interval, 0.77 to 0.96; P = 0.006). The results for the confirmatory secondary outcomes did not differ significantly between the two groups. The incidence of serious adverse events was 47.9% in the oral semaglutide group and 50.3% in the placebo group; the incidence of gastrointestinal disorders was 5.0% and 4.4%, respectively.</p><p><strong>Conclusions: </strong>Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events. (Funded by Novo Nordisk; SOUL ClinicalTrials.gov number, NCT03914326.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.","authors":"Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez, Claire Grange, Manuel Monreal, Juan J López-Núñez, Remedios Otero-Candelera, Grégoire Le Gal, Erik Yeo, Marc Righini, Helia Robert-Ebadi, Menno V Huisman, Frederikus A Klok, Peter Westerweel, Giancarlo Agnelli, Cecilia Becattini, Aristotelis Bamias, Kostas Syrigos, Sebastian Szmit, Adam Torbicki, Peter Verhamme, Anthony Maraveyas, Alexander T Cohen, Cihan Ay, Céline Chapelle, Guy Meyer, Francis Couturaud, Patrick Mismetti, Philippe Girard, Laurent Bertoletti, Silvy Laporte","doi":"10.1056/NEJMoa2416112","DOIUrl":"https://doi.org/10.1056/NEJMoa2416112","url":null,"abstract":"<p><strong>Background: </strong>In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and decreasing bleeding is unclear.</p><p><strong>Methods: </strong>We conducted a randomized, double-blind, noninferiority trial with blinded central outcome adjudication. Consecutive patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism who had completed at least 6 months of anticoagulant therapy were randomly assigned in a 1:1 ratio to receive oral apixaban at a reduced (2.5 mg) or full (5.0 mg) dose twice daily for 12 months. The primary outcome was centrally adjudicated fatal or nonfatal recurrent venous thromboembolism, assessed in a noninferiority analysis (margin of 2.00 for the upper boundary of the 95% confidence interval of the subhazard ratio). The key secondary outcome was clinically relevant bleeding, assessed in a superiority analysis.</p><p><strong>Results: </strong>A total of 1766 patients underwent randomization at a median time since the index event of 8.0 months (interquartile range, 6.5 to 12.6); 866 patients were assigned to the reduced-dose group, and 900 to the full-dose group. The median treatment duration was 11.8 months (interquartile range, 8.3 to 12.1). Recurrent venous thromboembolism occurred in 18 patients (cumulative incidence, 2.1%) in the reduced-dose group and in 24 (cumulative incidence, 2.8%) in the full-dose group (adjusted subhazard ratio, 0.76; 95% confidence interval [CI], 0.41 to 1.41; P = 0.001 for noninferiority). Clinically relevant bleeding occurred in 102 patients (cumulative incidence, 12.1%) in the reduced-dose group and in 136 (cumulative incidence, 15.6%) in the full-dose group (adjusted subhazard ratio, 0.75; 95% CI, 0.58 to 0.97; P = 0.03). Mortality was 17.7% in the reduced-dose group and 19.6% in the full-dose group (adjusted hazard ratio, 0.96; 95% CI, 0.86 to 1.06).</p><p><strong>Conclusions: </strong>Extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for the prevention of recurrent venous thromboembolism in patients with active cancer. The reduced dose led to a lower incidence of clinically relevant bleeding complications than the full dose. (Funded by the Bristol-Myers Squibb-Pfizer Alliance; API-CAT ClinicalTrials.gov number, NCT03692065.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-Associated Venous Thromboembolism - Beyond 6 Months.","authors":"Simon Noble","doi":"10.1056/NEJMe2503460","DOIUrl":"https://doi.org/10.1056/NEJMe2503460","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aortic Stenosis - When Valve Intervention Is Not Enough.","authors":"Ori Ben-Yehuda","doi":"10.1056/NEJMe2503345","DOIUrl":"https://doi.org/10.1056/NEJMe2503345","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":96.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case 9-2025: A 59-Year-Old Man with Hepatocellular Carcinoma.","authors":"Kathleen E Corey, David M Dudzinski, Alexander R Guimaraes, Mari Mino-Kenudson","doi":"10.1056/NEJMcpc1909622","DOIUrl":"https://doi.org/10.1056/NEJMcpc1909622","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"392 12","pages":"1216-1227"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red Urine after Administration of Hydroxocobalamin.","authors":"Nilesh Anand Devanand, Robin de Meirsman","doi":"10.1056/NEJMicm2413940","DOIUrl":"10.1056/NEJMicm2413940","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"e32"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.","authors":"Alexander Kempny, Colm McCabe","doi":"10.1056/NEJMc2501560","DOIUrl":"https://doi.org/10.1056/NEJMc2501560","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"392 12","pages":"1243"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}